Richard D. Carvajal, MD, discusses the mechanism of action and efficacy of tebentafusp-tebn for patients with uveal melanoma.
Richard D. Carvajal, MD
Advertisement
Articles by Richard D. Carvajal, MD
Richard D. Carvajal, MD, discusses 2 therapies in clinical trials registering patients with melanoma.
Richard D. Carvajal, MD, describes the design of a phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma.
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.
Advertisement
Latest Updated Articles
Using Selumetinib in Advanced Uveal MelanomaPublished: June 7th 2013 | Updated:
- The Design of a Trial Analyzing Selumetinib in Advanced Uveal Melanoma
Published: July 9th 2013 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
